Free Trial
NASDAQ:TSVT

2seventy bio Q1 2025 Earnings Report

2seventy bio logo
$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$22.94 million
Expected Revenue
$13.96 million
Beat/Miss
Beat by +$8.98 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

2seventy bio's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

2seventy bio Earnings Headlines

Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

View 2seventy bio Profile

More Earnings Resources from MarketBeat